NASDAQ$ACET
Adicet Bio Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Reported financial results and provided business updates for the third quarter ended September 30, 2023.
Adicet Bio reported a net loss of $49.9 million for the third quarter of 2023, including a goodwill impairment expense of $19.5 million. The company is focusing on advancing ADI-001 and ADI-270, with plans to file an IND for ADI-270 in the first half of 2024. Cash and cash equivalents were $183.3 million as of September 30, 2023, expected to fund operations into the first half of 2025.
- Initiated ADI-001 Phase 1 EXPAND cohort in post CAR T large B cell lymphoma (LBCL).
- Continuing to enroll mantle cell lymphoma (MCL) patients in ADI-001 Phase 1 study.
- Prioritizing ADI-270 for solid tumor applications; on track to file ADI-270 Investigational New Drug Application (IND) in 1H 2024.
- Presented new preclinical data at the International Conference on Molecular Targets and Cancer Therapeutics and three posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.
Headline financials
Revenue & EPS history
Adicet Bio · Revenue · Quarterly
$179K
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2023
+1.1%
Avg return
Earnings day
+1.2%
Avg return
5 days after
-5.0%
Avg return
30 days after
52%
16 / 31 earnings
Positive
+29.7%
Q4 2021
Best reaction
-9.1%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.4% | -5.3% | +1.4% | |
| Q4 2025 | -3.2% | -1.6% | -4.0% | |
| Q3 2025 | -3.6% | -6.4% | -22.6% | |
| Q1 2025 | -6.9% | -7.5% | -7.9% | |
| Q4 2024 | -2.3% | +15.0% | -33.8% | |
| Q3 2024 | +1.5% | -3.8% | -19.8% | |
| Q2 2024 | +7.9% | +20.5% | +20.5% | |
| Q1 2024 | -2.8% | +11.1% | +0.7% | |
| Q4 2023 | +9.7% | +12.3% | +3.8% | |
| Q3 2023 | -4.9% | -10.3% | +4.9% | |
| Q2 2023 | +6.8% | -2.7% | -23.2% | |
| Q1 2023 | +4.1% | -4.5% | -14.9% | |
| Q4 2022 | -3.1% | -19.5% | -29.5% | |
| Q3 2022 | +1.9% | +11.0% | +3.8% | |
| Q2 2022 | -9.1% | -11.0% | -4.9% | |
| Q1 2022 | +8.6% | +13.1% | +9.6% | |
| Q4 2021 | +29.7% | +31.0% | +37.6% | |
| Q3 2021 | +3.2% | +0.8% | +49.7% | |
| Q2 2021 | +8.1% | -5.9% | +6.4% | |
| Q1 2021 | +1.5% | +7.7% | -22.5% | |
| Q4 2020 | -0.7% | +6.2% | -11.2% | |
| Q3 2020 | +5.9% | +9.2% | +22.3% | |
| Q2 2020 | +0.4% | +4.4% | -17.3% | |
| Q1 2020 | +9.1% | +10.3% | +24.6% | |
| Q4 2019 | -8.5% | -17.1% | -6.0% | |
| Q3 2019 | -5.3% | +6.7% | -85.2% | |
| Q2 2019 | -3.5% | -3.7% | -22.2% | |
| Q1 2019 | -4.6% | -7.3% | +1.3% | |
| Q4 2018 | -8.3% | -10.8% | -23.3% | |
| Q3 2018 | -5.8% | -5.2% | -2.7% | |
| Q2 2018 | +5.1% | -0.9% | +9.3% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro